Precision NanoSystems NanoAssemblr Ignite for developing mRNA treatments and vaccines

Click2Contact

Messenger RNA (mRNA) treatments are novel, disruptive technologies that offer a promising alternative to conventional therapeutic approaches given high potency, capacity for rapid development to full GMP and potential for low-cost manufacture. Unmodified and base-modified mRNA vaccines, such as the current approach by Moderna, encode the antigen of interest and untranslated regions, whereas self-amplifying mRNAs (SAM) are void of structural proteins (inherently safe) and encode not only the antigen but also the viral replication machinery that supports intracellular RNA amplification and abundant protein expression. This facilitates generous antigen production from an extremely small dose of vaccine.

RNA is susceptible to degradation in biological fluids. Lipid nanoparticles (LNP) are designed specifically to overcome the RNA delivery challenge. They co-opt endogenous uptake mechanisms to efficiently deliver RNA to cells in vitro and in vivo. GenVoy-ILM is a pre-optimised, easy-to-use lipid mixture designed to encapsulate RNA (mRNA, gRNA, siRNA, miRNA, tRNA) for delivery to cells.

The NanoAssemblr platform from Precision Nanosystems enables the rapid, reproducible and scalable manufacture of next-generation nanoparticle formulations such as lipid nanoparticles and liposomes to encapsulate a payload such as a SAM. NxGen microfluidics mixing technology simplifies and accelerates nanomedicine formulation by enabling all scales of development through one single mixing element — from formulation to full GMP.

For more information: https://youtu.be/dqy6O68yxmg.